Immunologic Monitoring and Cell Products Laboratory, University of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Immunologic Monitoring and Cell Products Laboratory, University of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Cytotherapy. 2022 Jan;24(1):32-36. doi: 10.1016/j.jcyt.2020.12.015. Epub 2021 Feb 17.
Immunotherapy of cancer and other diseases is often dependent on adoptive transfer to patients of cellular products generated in Current Good Manufacturing Practice (cGMP) facilities. With the availability and approval of various cellular products for therapy, cell production facilities are experiencing unprecedented growth in demand for services. Increasingly, these services involve processing of externally generated cells for transfer to the bedside. The arrival of cells from external manufacturing facilities for processing and eventual infusion of cell therapy products into patients creates a new layer of responsibility and adds to an already demanding list of the existing procedures in academic cGMP facilities. Sponsors introduce their own requirements for the handling of cells that the laboratory must incorporate and follow. The challenges of creating additional access to cleanrooms, writing new standard operating procedures, expanding personnel training, altering pre-existing schedules and incorporating additional monitoring for safety of external products alter the balance of laboratory operations. Adjustments for accommodating externally manufactured products are numerous and varied, as each sponsor has requests that are product-specific. If cells produced by several different external manufacturers are handled by the same facility, the negative impact on the regular activities in this facility may be considerable. Here the authors provide a review of operational challenges that an academic-based laboratory faces and discuss solutions that could ameliorate the difficulties related to an increasing volume of industry-sponsored trials. The solution may be the development under the auspices of the Foundation for Accreditation of Cellular Therapy or the Food and Drug Administration of regulations that will guide the processing of products manufactured by external companies and make these regulations broadly applicable in all cGMP facilities.
癌症和其他疾病的免疫疗法通常依赖于在现行良好生产规范 (cGMP) 设施中生成的细胞产品向患者的过继转移。随着各种细胞产品治疗的可用性和批准,细胞生产设施对服务的需求正在经历前所未有的增长。越来越多的这些服务涉及处理外部生成的细胞以转移到床边。来自外部制造设施进行加工并最终将细胞治疗产品输注到患者体内的细胞的到来,为学术 cGMP 设施中的现有程序增加了一层新的责任,并增加了已经苛刻的要求列表。赞助商提出了自己的细胞处理要求,实验室必须将这些要求纳入并遵循。为增加对洁净室的访问、编写新的标准操作程序、扩大人员培训、改变预先存在的时间表以及纳入外部产品安全性的额外监测而创建的额外访问权限,改变了实验室运营的平衡。为容纳外部制造产品而进行的调整是多种多样的,因为每个赞助商都有特定于产品的要求。如果同一设施处理由几个不同的外部制造商生产的细胞,则对该设施的正常活动的负面影响可能相当大。在这里,作者回顾了基于学术的实验室面临的运营挑战,并讨论了可能缓解与越来越多的行业赞助试验相关的困难的解决方案。解决方案可能是在细胞治疗认证基金会或食品和药物管理局的主持下制定法规,这些法规将指导外部公司制造的产品的处理,并使这些法规在所有 cGMP 设施中广泛适用。